Evidence map›Paper›PMID 42356193›Full record

ArticleMedicina (Kaunas, Lithuania)2026

Early PSA Decline Predicts Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Retrospective Single-Center Study.

Engin Hendem, Mehmet Zahid Koçak, Oguzhan Yıldız, Mustafa Korkmaz, Muhammed Muhiddin Er, Murat Araz, Mehmet Artac, Melek Karakurt Eryılmaz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Engin HendemDepartment of Medical Oncology, Erzincan Mengücek Gazi Eğitim ve Araştırma Hastanesi, 24100 Erzincan, Turkey.ORCID 0000-0001-6970-4733
Mehmet Zahid KoçakDepartment of Medical Oncology, Necmettin Erbakan University, 42090 Konya, Turkey.ORCID 0000-0003-3085-7964
Oguzhan YıldızDepartment of Medical Oncology, Necmettin Erbakan University, 42090 Konya, Turkey.
Mustafa KorkmazDepartment of Medical Oncology, Süleyman Demirel University, 32260 Isparta, Turkey.ORCID 0000-0003-0926-6748
Muhammed Muhiddin ErDepartment of Medical Oncology, Konya City Hospital, 42020 Konya, Turkey.ORCID 0000-0002-0583-0295
Murat ArazDepartment of Medical Oncology, Necmettin Erbakan University, 42090 Konya, Turkey.ORCID 0000-0002-4632-9501
Mehmet ArtacDepartment of Medical Oncology, Necmettin Erbakan University, 42090 Konya, Turkey.ORCID 0000-0003-2335-3354
Melek Karakurt EryılmazDepartment of Medical Oncology, Necmettin Erbakan University, 42090 Konya, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Androgen Receptor AntagonistsProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantAbiraterone AcetateAgedAged, 80 and overBenzamidesHumansKaplan-Meier EstimateMaleMiddle AgedNitrilesPhenylthiohydantoinPrognosisProportional Hazards ModelsRetrospective StudiesAbiraterone AcetateAndrogen Receptor AntagonistsBenzamidesenzalutamideNitrilesPhenylthiohydantoinProstate-Specific Antigenabirateroneandrogen receptor pathway inhibitorsenzalutamidemetastatic castration-resistant prostate cancerPSA declinesurvival outcomes

Identifiers

PMID42356193
PMCPMC13302889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.